

Takeda

Takeda is a global, values-based, R&D-driven biopharmaceutical leader, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. More than 50,000 employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. Another key element of Takeda's commitment to building Better Health for People, Brighter Future for the World is protecting our shared environment and advancing innovation in environmental sustainability.

Takeda was founded in Japan in 1781 and is headquartered in Tokyo. Our values are laid out in our company philosophy of Takeda-ism.


TAKEDA-ISM



OUR VALUES ARE A CLEAR COMPASS FOR OUR DAILY ACTIONS, WHICH PLACE THE PATIENT AT THE HEART OF OUR WORK.

Global Therapeutic Areas

Takeda focuses on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Specifically, Takeda showcases a comprehensive product portfolio covering a wide spectrum of rare and complex diseases, as reflected in the company's global therapeutic & focus areas:



Rare diseases impact many people

- The definition of a rare disease in Switzerland is **less than 5 in 10,000 people**
- In Switzerland **more than 500'000 people are affected by rare diseases**, most of them children

Global disease burden

- There are between **6'000 - 8'000 different rare diseases**, most of them ultra-rare
- **~85% of rare diseases affect less than 1 in 1'000'000 people**
- **~50% of patients with rare diseases are children**
- **~30% of children diagnosed do not live to their 5th birthday**
- It takes up to **6 to 8 years** to get an accurate rare diagnosis
- For **~95% of rare diseases there is no approved therapy**



TAKEDA SWITZERLAND

Takeda has an important footprint in Switzerland. Takeda's Head Office in Opfikon, Zurich hosts the regional headquarters of Takeda and the Swiss Affiliate, Takeda Pharma AG. Takeda entered the Swiss market in 1986 under the name Takeda Pharma AG. Takeda Pharma AG is responsible for the distribution of medicines for the Swiss market. Around 1,200 personnel work at this site.

Takeda Neuchâtel Manufacturing Site was founded in 1996 as the first biotechnology manufacturing site ever established in the Neuchâtel Canton. Takeda Neuchâtel Manufacturing Site is specialized in blood bleeding disorders therapies. Today, the site employs 700 collaborators and produces three recombinant clotting factors for the global market.



ZURICH HEAD OFFICE

HEAD OFFICE FOR EUROPE & CANADA
Regional headquarters of Takeda, hub location for global functions & business units

~1200
EMPLOYEES



BY GENDER
50% WOMEN • 50% MEN



~61
NATIONALITIES



TOP
TOP EMPLOYER
CERTIFIED



SWISS AFFILIATE



>50
PRODUCTS
ON THE
MARKET



LEADER
IN RARE
DISEASES



~90
EMPLOYEES



BY GENDER
70% WOMEN
30% MEN



NEUCHÂTEL MANUFACTURING SITE

Biotechnology manufacturing site specialized in recombinant bleeding disorders therapies

~700
EMPLOYEES



BY GENDER
40% WOMEN • 60% MEN



22
NATIONALITIES



PIONEER BIOTECHNOLOGY MANUFACTURING SITE

1st site producing and commercializing recombinant Factor VIII

1st and unique site producing and commercializing recombinant Von Willebrand Factor



SUPPLY
70+ COUNTRIES
WORLDWIDE



PRODUCTION
24/7 • 365/365



PRODUCTS

Two recombinant products to treat Hemophilia A (Factor VIII)

One recombinant product to treat Von Willebrand Syndrome (Von Willebrand Factor)